脑血疏口服液对基底节区脑出血患者术后康复和生存质量的影响

Effect of Naoxueshu Oral Liquid on postoperative rehabilitation and quality of life of patients with intracerebral hemorrhage in the basal ganglia

目的分析脑血疏口服液对基底节区脑出血患者术后康复和生存质量的影响。方法采用前瞻性研究方法,将2019年12月至2021年1月就诊于河南中医药大学第一附属医院的因基底节区脑出血行微创脑内血肿穿刺抽吸引流术的83例患者纳入研究,根据随机数字表法分为两组,观察组40例,对照组43例。对照组患者术后不使用脑血疏口服液,观察组患者术后1 d给予脑血疏口服液(10 mL/次,每日3次,持续用药30 d)。观察治疗前和治疗30 d后两组患者血清S100蛋白、水通道蛋白4(AQP4)、肿瘤坏死因子α(TNF-α)、白细胞介素6(IL-6)、白细胞介素4(IL-4)水平。记录两组患者治疗前、治疗3、7、14 d后血肿体积和治疗3 d血肿扩大发生率。观察两组治疗前和治疗30 d后美国国立卫生研究院卒中量表(NIHSS)评分、Barthel指数(BI)评分;评估预后及不良反应发生情况。结果治疗30 d后,两组血清S100蛋白、AQP4、TNF-α、IL-6、IL-4水平均较治疗前降低(P<0.05),且观察组较对照组更低。治疗3、7、14 d后两组脑血肿体积均缩小(P<0.05),且观察组较对照组缩小更明显。观察组治疗3 d后血肿扩大发生率(2.50%)低于对照组(18.37%),差异有统计学意义(P<0.05)。治疗30 d后两组患者NIHSS分值均降低(P<0.05),且观察组较对照组降低更明显,两组BI分值均提高(P<0.05),且观察组高于对照组。观察组预后良好率(90.00%)高于对照组(72.09%),P<0.05。观察组出现1例恶心、2例腹胀、1例腹泻;对照组出现1例恶心、1例腹泻。结论脑血疏口服液能缓解基底节区脑出血患者术后炎症反应,促进水肿缓解和血肿吸收,改善神经功能,提高生存质量,用药安全,值得推广。

Objective To analyze the effect of Naoxueshu Oral Liquid on postoperative rehabilitation and quality of life of patients with basal ganglia cerebral hemorrhage.Methods In this prospective study,83 patients with basal ganglia cerebral hemorrhage undergoing concurrent operation in the First Affiliated Hospital of Henan University of Traditional Chinese Medicine from December 2019 to January 2021 were planned to be included.They were divided into two groups by random number table method,there were 40 cases in the observation group and 43 cases in the control group.The observation group was given Naoxueshu Oral Liquid 10 mL tid.1 d after surgery continuously for 30 d,and the control group was not given Naoxueshu Oral Liquid after surgery.The serum levels of S100 protein,aquaporin 4(AQP4),tumor necrosis factor-α(TNF-α),interleukin-6(IL-6),interleukin-4(IL-4)in both groups were observed before treatment and 30 d after treatment.The volume of hematoma before treatment,at 3 d,7 d and 14 d,and the rate of hematoma expansion at 3 d were recorded.National Institutes of Health stroke scale(NIHSS)score and Barthel index(BI)score were observed before treatment and 30 d after treatment.The efficacy and prognosis were evaluated.Adverse reactions were recorded.Results After 30 d of treatment,serum S100 protein,AQP4,TNF-α,IL-6 and IL-4 levels in both groups were lower than baseline(P<0.05),and lower in the observation group than the control group.After treatment for 3 d,7 d and 14 d,the volume of cerebral hematoma decreased in both groups(P<0.05),and the reduction in the observation group was more obvious than that in the control group.The incidence of hematoma enlargement in the observation group(2.50%)was lower than that in the control group(18.37%)(P<0.05).After 30 d of treatment,the NIHSS scores in both groups decreased(P<0.05),and that in the observation group decreased more significantly than the control group.The BI scores in both groups increased(P<0.05),and that in the observation group was higher than the control group.The good prognosis rate of the observation group(90.00%)was higher than the control group(72.09%)(P<0.05).In the observation group,there were 1 case of nausea,2 cases of abdominal distension,and 1 case of diarrhea;in the control group,there were 1 case of nausea,1 case of diarrhea.Conclusion Naoxueshu Oral Liquid can relieve postoperative inflammatory reaction in patients with cerebral hemorrhage in the basal ganglia,promote edema relief and hematoma absorption,improve nerve function,improve quality of life,and is safe to use.It is worthy of promotion in clinical practice.